Delcath Systems, Inc. (DCTH) is a publicly traded company in the Healthcare — Medical - Devices industry listed on NASDAQ. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
Delcath Systems, Inc. is an interventional oncology firm operating in the United States and Europe, dedicated to developing treatments for both primary and secondary liver cancers. Its leading investigational product is the HEPZATO KIT, a unique hepatic delivery system for melphalan that targets high-dose chemotherapy specifically to the liver. This innovative approach aims to substantially reduce systemic drug exposure and mitigate associated side effects.
Analysis Summary
Delcath Systems, Inc. reported revenue of $85.2M in the most recent fiscal year, growing at a 5-year CAGR of 120.2%.
Trailing-twelve-month margins: gross margin 87.1%, operating margin -1.9%, net margin 0.6%.
At the current price of $16.22, DCTH trades at a P/E of 1467.87 and an ROE of 0.46%. Market capitalisation stands at $560M.
Balance sheet quality for DCTH: current ratio of 10.9, net cash position of $90.1M. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Cash flow quality is strong: free cash flow of $21.0M represents 777% conversion of reported net income. High conversion (above 90%) suggests earnings translate cleanly into cash; lower conversion may indicate working capital tightness or accounting timing differences.
Price
| Price | $16.22 |
| Market Cap | $560M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| P/E Ratio | 1467.87 |
| Price / Book | 4.78 |
| EV / EBITDA | 297.45 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | 0.46% |
| Return on Invested Capital | -0.60% |
| Return on Assets | 0.39% |
| Gross Margin | 87.05% |
| Operating Margin | -1.90% |
| Net Margin | 0.56% |
Financial Health
| Debt / Equity | 0.02 |
| Current Ratio | 9.83 |
What to look at in Healthcare / Pharma
The R&D pipeline is the invisible asset. Patents expiring = revenues evaporating. Look at innovation and cash flow.
- R&D / Revenue — Shows investment in future pipeline. Serious pharma reinvests 15-20%
- 5y EPS growth — After patent expirations, are they still growing?
- Gross margin — Branded pharma >70%. Generics much lower — defines the business type
- FCF / Net Income — Earnings quality — big pharma should convert >90%
- ROIC — Capital reinvested efficiently — key in pharma due to long R&D cycles
- Net debt / EBITDA — Pharma acquisitions pile up debt — watch the post-M&A picture
- P/E vs own 10y history — The best comparison is with its own history, not with peers
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| DCTH | Delcath Systems, Inc. | $560M | 1467.87 | 4.78 | 0.5% |
| ABT | Abbott Laboratories | $177.1B | 32.49 | 3.45 | 10.5% |
| 0Y6X.L | Medtronic Plc | $125.7B | |||
| MDT | Medtronic plc | $118.5B | 22.97 | 2.39 | 10.6% |
| SYK | Stryker Corporation | $109.2B | 29.95 | 4.66 | 16.4% |
| 0R2S.L | Stryker Corporation | $107.9B | 29.27 | 4.55 | 16.4% |
| 0HOY.L | Boston Scientific Corporation | $66.5B | 48.91 | 5.86 | 11.9% |
| BSX | Boston Scientific Corporation | $65.3B | 17.73 | 2.61 | 14.9% |
Price Performance
| 1 month | -3.80% |
| 3 months | +38.75% |
| Year-to-date | +60.59% |
| 1 year | +44.82% |
| 3 years | +268.64% |
| 5 years | +77.85% |
52-Week Range
| 52-week High | $17.42 |
| 52-week Low | $8.12 |
| Avg Volume (90d) | 527K |
Related companies: AGL · BWAY · CERS · MASS · NAKA · NPCE · RXST
Explore sector: Healthcare · Medical - Devices
More sections of DCTH: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks